Based on 1 analysts giving stock ratings to Revelation Biosciences Inc in the past month.
In the current month, REVB has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. REVB average Analyst price target in the last month is 124.250.
Based on analysts' estimates, REVB EPS is projected to reach -6.080 in FY2026Q4, following reported EPS of -41.474 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -41.47, while Revelation Biosciences IncREVB's earnings per share (EPS) for the previous quarter was USD -6.08. EPS for the next quarter is expected at USD -6.08.